Takeda's PhII meza­gi­ta­m­ab da­ta; Apogee's $483M raise; Gal­der­ma's IPO

Plus, news about Cy­bin, Mer­ck, Almi­rall, Eloxx Phar­ma­ceu­ti­cals and BioVie:

Take­da drug passed Phase II test: The pro­gram, meza­gi­ta­m­ab (TAK-079), is be­ing test­ed in per­sis­tent or chron­ic pri­ma­ry im­mune throm­bo­cy­tope­nia (ITP). An in­ter­im analy­sis showed pos­i­tive safe­ty and ef­fi­ca­cy re­sults, per a press re­lease, though ex­act da­ta fig­ures were not dis­closed. — Max Gel­man

Apogee clos­es $483 mil­lion of­fer­ing: The raise, up from an ini­tial­ly es­ti­mat­ed $350 mil­lion, comes a week af­ter Apogee’s atopic der­mati­tis treat­ment im­pressed Wall Street in a Phase I healthy vol­un­teer study — shares are up 100% since the start of March. — Max Gel­man

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER